Overview

The Effect of Liraglutide on the GIT

Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Liraglutide is a glucose-like peptide 1 agonist, currently used as an effective weight-loss treatment. Its mechanism of action has not yet been elucidated. We want to investigate whether liraglutide affects MMC activity, gastrointestinal hormone release, glucose whole blood levels, hunger ratings and ad libitum food intake in healthy volunteers.
Phase:
Phase 4
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Treatments:
Liraglutide